Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.73 EUR | -4.02% | +17.54% | +33.88% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.88% | 138M | |
+4.29% | 43.43B | |
+47.87% | 41.69B | |
+9.24% | 41.31B | |
-10.82% | 27.14B | |
+9.26% | 25.28B | |
-24.44% | 18.47B | |
+34.49% | 12.59B | |
+1.79% | 12.33B | |
+8.85% | 11.03B |
- Stock Market
- Equities
- OSE Stock
- News OSE Immunotherapeutics
- OSE Immunotherapeutics : Servier Enroll First Patient In Phase-Two Study Of Sjögren’s Syndrome Drug